Carnegie Capital Asset Management, LLC Crispr Therapeutics Ag Transaction History
Carnegie Capital Asset Management, LLC
- $3.18 Billion
- Q2 2024
A detailed history of Carnegie Capital Asset Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Carnegie Capital Asset Management, LLC holds 102,112 shares of CRSP stock, worth $4.56 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
102,112
Previous 67,612
51.03%
Holding current value
$4.56 Million
Previous $4.61 Million
19.68%
% of portfolio
0.17%
Previous 0.14%
Shares
21 transactions
Others Institutions Holding CRSP
# of Institutions
523Shares Held
58MCall Options Held
1.73MPut Options Held
1.84M-
Capital International Investors Los Angeles, CA7.87MShares$351 Million0.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.78MShares$347 Million3.82% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.15MShares$141 Million0.13% of portfolio
-
Nikko Asset Management Americas, Inc.3.15MShares$141 Million1.99% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$124 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.48B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....